Literature DB >> 33200187

Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?

André Heinen1, Anja Schnabel1, Normi Brück1, Martin Smitka2, Christine Wolf1, Nadja Lucas1, Stefanie Dollinger3, Gabriele Hahn4, Claudia Günther5, Reinhard Berner1, Min Ae Lee-Kirsch1, Catharina Schuetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33200187     DOI： 10.1093/rheumatology/keaa657

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response.

Authors:  Butsabong Lerkvaleekul; Saskia R Veldkamp; M Marlot van der Wal; Ellen J H Schatorjé; Sylvia S M Kamphuis; J Merlijn van den Berg; Petra C E Hissink Muller; Wineke Armbrust; Sebastiaan J Vastert; Judith Wienke; Marc H A Jansen; Annet van Royen-Kerkhof; Femke van Wijk
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 2.  Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Authors:  Kareem G Elhage; Raymond Zhao; Mio Nakamura
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-08

3.  Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis.

Authors:  Zhaoling Wang; Qi Zheng; Wenjie Xuan; Xisheng Xu; Meiping Lu; Jianqiang Wu; Lixia Zou; Yiping Xu; Xuefeng Xu
Journal:  Front Pediatr       Date:  2022-09-20       Impact factor: 3.569

Review 4.  Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Authors:  Hanna Kim
Journal:  Curr Opin Rheumatol       Date:  2021-09-01       Impact factor: 4.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.